Embecta Corp., a medical device company, provides solutions to improve the health and wellbeing of people living with diabetes in the United States and internationally. The company's products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. It primarily sells its products to wholesalers and distributors. The company was formerly known as Berra Newco, Inc. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey.…
Why Embecta Bears Were Right Before A 54% Drop
Embecta (NASDAQ: EMBC) is listed on Nasdaq, where its shares trade in USD. It belongs to the Medical Instruments & Supplies industry, part of the Healthcare sector, and reports about 1,850 employees.
The shares were at 6.020 USD on 20 November 2026, down 55.1% over 52 weeks. Its 52-week range is 2.770 USD to 14.91 USD: the price is 59.6% below the high and 117.3% above the low.
At a market capitalisation of 341.09M USD, it trades at 4.1 times trailing earnings and 3.4 times forward earnings. The median trailing P/E of its 19 largest Medical Instruments & Supplies peers is 48.3, a discount of 92% for EMBC. It pays a dividend yielding 0.65% (it pays out 31% of its earnings), against a median of 0.92% among the dividend payers in that peer group.
Embecta reports return on equity of -14.6%, an operating margin of 23.3% and revenue down 8.1% year over year.
Its debt exceeds its cash by 1.29B USD. Its Piotroski F-score is 6 out of 9, an average reading of its financial health. 2 analysts cover the stock; their mean price target of 4.000 USD is 33.6% below the current price. The next earnings report is expected on 24 November 2026.